Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC

Gout Detected from a Simple Blood Sample

By Labmedica International staff writers
Posted on 31 Oct 2013
An in vitro diagnostic test, which detects active Gout disease from samples of whole blood, has been launched in Europe.

The CE marked GoutiFind test takes a new approach to Gout diagnosis. Based on a key scientific discovery of how our immune system reacts to uric acid crystal deposition in joints, the GoutiFind test measures the cellular immune response to the deposits. No special clinical setting is required for the GoutiFind test. A fresh blood sample drawn in a physician’s office or clinical laboratory is all that is required for the GoutiFind test.

The GoutiFind test is offered throughout the EU as a diagnostic service by Boulder Diagnostics (Mellrichstadt, Germany) clinical diagnostic service laboratory. The GoutiFind test detects active Gout disease without employing the unreliable determination of the uric acid level. It therefore provides a noninvasive reliable diagnosis of Gout disease.

The GoutiFind test can replace the invasive joint puncture method for Gout detection and thus make reliable Gout diagnosis available to a much broader range of medical institutions and physician practices. The test is based on measuring the cellular immune response to a specific challenge with a Gout stimulus.

"The GoutiFind test simplifies and makes Gout diagnosis more broadly available," commented Dr. Wolfgang Pieken, CEO of Boulder Diagnostics Inc., and added, "the GoutiFind test is the second product from our technology platform that queries the trained immunity for active disease."

"At our clinical laboratory in Mellrichstadt, Germany, we now accept whole blood samples for Gout detection by the GoutiFind method," stated Dr. Anton Waldherr, laboratory physician of Boulder Diagnostics Europe GmbH.

Related Links:

Boulder Diagnostics



KARL HECHT GMBH & CO KG
DiagCor Bioscience
CELLAVISION AB
comments powered by Disqus
Sekisui Diagnostics

Channels

Industry News

view channel

Roche Acquires High-Precision Dissection Technology from AvanSci Bio

Roche Diagnostics of the Roche group (Basel, Switzerland) has signed a definitive Asset Purchase Agreement with AvanSci Bio (Salt Lake City, UT, USA) for all products associated with the high-performance microdissection of slide-mounted tissue sections for subsequent molecular analysis. The system consists of instrumentation,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.